Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Change in Acquisitions & Divestments (2020 - 2022)

Historic Change in Acquisitions & Divestments for Ascendis Pharma A (ASND) over the last 3 years, with Q4 2022 value amounting to -$54.1 million.

  • Ascendis Pharma A's Change in Acquisitions & Divestments rose 6586.81% to -$54.1 million in Q4 2022 from the same period last year, while for Sep 2023 it was -$54.1 million, marking a year-over-year increase of 8347.96%. This contributed to the annual value of -$218.2 million for FY2022, which is 1562.73% up from last year.
  • As of Q4 2022, Ascendis Pharma A's Change in Acquisitions & Divestments stood at -$54.1 million, which was up 6586.81% from -$71.7 million recorded in Q3 2022.
  • Over the past 5 years, Ascendis Pharma A's Change in Acquisitions & Divestments peaked at -$13.2 million during Q3 2021, and registered a low of -$235.3 million during Q4 2020.
  • For the 3-year period, Ascendis Pharma A's Change in Acquisitions & Divestments averaged around -$84.7 million, with its median value being -$60.9 million (2022).
  • In the last 5 years, Ascendis Pharma A's Change in Acquisitions & Divestments soared by 8944.0% in 2021 and then tumbled by 44374.09% in 2022.
  • Ascendis Pharma A's Change in Acquisitions & Divestments (Quarter) stood at -$235.3 million in 2020, then soared by 32.67% to -$158.4 million in 2021, then surged by 65.87% to -$54.1 million in 2022.
  • Its last three reported values are -$54.1 million in Q4 2022, -$71.7 million for Q3 2022, and -$67.6 million during Q2 2022.